XML 35 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
GOODWILL AND INTANGIBLE ASSETS
 12 Months Ended
Mar. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
The changes in the carrying amount of goodwill by operating segment for fiscal 2024 and 2023 are as follows:
(In thousands)PlasmaBlood CenterHospitalTotal
Carrying amount as of April 2, 2022$29,043 $34,166 $404,078 $467,287 
Currency translation— (311)(745)(1,056)
Carrying amount as of April 1, 202329,043 33,855 403,333 466,231 
Acquisitions— — 87,079 87,079 
Purchase accounting adjustments— — 12,283 12,283 
Currency translation— (371)(140)(511)
Carrying amount as of March 30, 2024$29,043 $33,484 $502,555 $565,082 

The results of the Company’s goodwill impairment test performed in the fourth quarter of fiscal 2024, 2023 and 2022 indicated that the estimated fair value of all reporting units exceeded their respective carrying values. There were no reporting units at risk of impairment as of the fiscal 2024, 2023 and 2022 annual test dates.
The gross carrying amount of intangible assets and the related accumulated amortization as of March 30, 2024 and April 1, 2023 is as follows:
(In thousands)Gross Carrying
Amount		Accumulated
Amortization		Net
As of March 30, 2024  
Amortizable:
Developed technology$464,291 $178,413 $285,878 
Customer contracts and related relationships255,144 190,033 65,111 
Capitalized software84,837 69,491 15,346 
Patents and other24,504 11,820 12,684 
Trade names14,320 5,456 8,864 
Total$843,096 $455,213 $387,883 
Non-amortizable:
In-process research and development$13,667 
In-process software development4,567 
Total$18,234 
(In thousands)Gross Carrying
Amount		Accumulated
Amortization		Net
As of April 1, 2023  
Amortizable:
Developed technology$362,506 $153,099 $209,407 
Customer contracts and related relationships203,240 187,774 15,466 
Capitalized software78,962 60,776 18,186 
Patents and other18,504 10,831 7,673 
Trade names9,508 4,942 4,566 
Total$672,720 $417,422 $255,298 
Non-amortizable:
In-process research and development$13,667 
In-process software development3,841 
In-process patents2,965 
Total$20,473 

In fiscal 2024, the Company acquired OpSens and recorded $114.9 million of developed technology, $52.3 million of customer contracts and related relationships and $4.8 million of trade names. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisition.

In fiscal 2024, the Company recorded an intangible asset impairment charge of $10.4 million related to the intangibles acquired as part of the enicor GmbH acquisition completed in fiscal 2021 within the Hospital business unit.

Intangible assets include the value assigned to license rights and developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years.

Aggregate amortization expense for amortized intangible assets for fiscal 2024, 2023 and 2022 was $41.4 million, $42.1 million and $56.6 million, respectively.
Amortization expense on intangible assets for the next five years is estimated to be as follows:
(In thousands)
Fiscal 2025$44,016 
Fiscal 2026$37,407 
Fiscal 2027$35,228 
Fiscal 2028$33,456 
Fiscal 2029$32,378 

For costs incurred related to the development of software to be sold, leased, or otherwise marketed, the Company applies the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. The costs capitalized for each project are included in intangible assets in the consolidated financial statements.

The Company capitalized $6.6 million and $3.8 million in software development costs for ongoing initiatives during fiscal 2024 and 2023, respectively. At March 30, 2024 and April 1, 2023, the Company had a total of $89.4 million and $82.8 million of software costs capitalized, of which $4.6 million and $3.8 million are related to in process software development initiatives, respectively, and the remaining balance represents in-service assets that are being amortized over their useful lives. Amortization expense for capitalized software was $8.6 million, $8.5 million and $8.4 million for fiscal 2024, 2023 and 2022, respectively.